Scott Got­tlieb clears an­oth­er hur­dle in last stretch ahead of the FDA; Sanofi inks €250M bis­pe­cif­ic dis­cov­ery deal in meta­bol­ics

→ The Sen­ate vot­ed to end de­bate on Scott Got­tlieb’s nom­i­na­tion to run the FDA, set­ting up a fi­nal vote that is wide­ly ex­pect­ed to con­firm him in the po­si­tion.

→ Scot­land’s Ex­sci­en­tia forged a strate­gic re­search deal with Sanofi cov­er­ing meta­bol­ic dis­ease. Ex­sci­en­tia will go to work look­ing for new bis­pecifics, and Sanofi will pro­vide re­search fund­ing and up to €250 mil­lion in mile­stones. An­drew Hop­kins, CEO, Ex­sci­en­tia said: “We are de­light­ed that Sanofi is en­gag­ing with Ex­sci­en­tia in a com­pre­hen­sive, end-to-end drug dis­cov­ery project. This agree­ment high­lights Ex­sci­en­tia’s abil­i­ty to ap­ply bis­pe­cif­ic drug de­sign in a com­pre­hen­sive and high­ly pro­duc­tive man­ner.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.